Relmada Therapeutics, Inc. (RLMD)
| Market Cap | 779.32M +6,134.6% |
| Revenue (ttm) | n/a |
| Net Income | -57.39M |
| EPS | -1.45 |
| Shares Out | 104.89M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 679,817 |
| Open | 7.84 |
| Previous Close | 7.86 |
| Day's Range | 7.27 - 7.84 |
| 52-Week Range | 0.32 - 8.00 |
| Beta | 0.43 |
| Analysts | Strong Buy |
| Price Target | 12.40 (+66.89%) |
| Earnings Date | May 12, 2026 |
About RLMD
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for RLMD stock is "Strong Buy." The 12-month stock price target is $12.4, which is an increase of 66.89% from the latest price.
News
Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026
CORAL GABLES, Fla., May 06, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for on...
Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026
CORAL GABLES, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for on...
Relmada Therapeutics initiated with an Overweight at Piper Sandler
Piper Sandler initiated coverage of Relmada Therapeutics (RLMD) with an Overweight rating and $12 price target The firm says the company is advancing NDV-01, a novel intravesicle treatment for non-mus...
Relmada Therapeutics price target raised to $19 from $10 at Mizuho
Mizuho analyst Uy Ear raised the firm’s price target on Relmada Therapeutics (RLMD) to $19 from $10 and keeps an Outperform rating on the shares. The company reported “productive” Q4
Relmada Therapeutics Earnings Call Transcript: Q4 2025
2025 saw major clinical and financial milestones, including strong NDV-01 phase II data, FDA alignment for phase III, and a $160M financing extending runway through 2029. NDV-01's efficacy and safety profile position it as a potential best-in-class NMIBC therapy.
Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
CORAL GABLES, Fla., March 19, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for ...
Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026
CORAL GABLES, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for ...
Relmada Therapeutics Transcript: Leerink Global Healthcare Conference 2026
NDV-01, a sustained-release Gem/Doce gel for bladder cancer, shows high 12-month CR rates and favorable safety, with pivotal trials starting mid-year. The company raised $160 million to support development, aiming for broad adoption in both high- and intermediate-risk settings.
Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference
CORAL GABLES, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for ...
Why Is Relmada Therapeutics Stock (RLMD) Up Today?
Relmada Therapeutics stock took off after the company announced new study results and financing.
Relmada Therapeutics prices 29.47M shares at $4.75 in private placement
Relmada Therapeutics (RLMD) has entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $160M to
Relmada Therapeutics reports 12-month Phase 2 interim data for NDV-01
Relmada Therapeutics (RLMD) announced 12-month interim data from its ongoing Phase 2 trial evaluating NDV-01 in patients with high-risk non-muscle invasive bladder cancer. The Phase 2 trial of NDV-01 ...
Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing
CORAL GABLES, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for ...
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer
Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBC BCG-unresponsive patients achieved an 80% CR rate at 12 months and 94% CR rate at any time Tolerabi...
Relmada Therapeutics initiated with a Buy at Lucid Capital
Lucid Capital initiated coverage of Relmada Therapeutics (RLMD) with a Buy rating and $14 price target Relmada is a clinical-stage biotechnology whose core focus is on NDV-01, a sustained-release form...
Relmada Therapeutics assumed at Outperform from Market Perform at Leerink
Leerink upgraded Relmada Therapeutics (RLMD) to Outperform from Market Perform with an $8 price target as the analyst assumed coverage of the stock. The clinical-stage biotechnology company is focused...
Relmada Therapeutics provides regulatory update on FDA alignment for NDV-01
Relmada Therapeutics (RLMD) announced that it has received written feedback from the U.S. Food and Drug Administration, FDA, regarding the registrational development pathway for NDV-01 in 2nd-line ref...
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications
FDA written feedback supports: - a single-arm, open-label registrational trial in 2nd-line refractory high-grade NMIBC with CIS - a randomized vs observation single trial in intermediate-risk NMIBC in...
Relmada Therapeutics initiated with a Buy at Jefferies
Jefferies initiated coverage of Relmada Therapeutics (RLMD) with a Buy rating and $9 price target The firm says the company has undergone a transformation in 2025, shifting from a failed
Relmada Therapeutics to present NDV-01 Phase 2 data at SUO meeting
Relmada Therapeutics (RLMD) announced that the previously disclosed 6-month follow-up data from the ongoing Phase 2 study of NDV-01, a sustained release, intravesical formulation of gemcitabine and do...
Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology
Poster highlights 6-month follow-up data from the ongoing Phase 2 trial of NDV-01 in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Relmada plans to advance NDV-01, a sustai...
Mizuho upgrades Relmada to Outperform with ‘more upside’ ahead
Mizuho upgraded Relmada Therapeutics (RLMD) to Outperform from Neutral with a price target of $10, up from $1. The shares are up over 660% in 2025 due to excitement about
Relmada Therapeutics upgraded to Outperform from Neutral at Mizuho
Mizuho upgraded Relmada Therapeutics (RLMD) to Outperform from Neutral with a price target of $10, up from $1. Published first on TheFly – the ultimate source for real-time, market-moving breaking
Relmada Therapeutics Earnings Call Transcript: Q3 2025
Strong nine-month phase II data for NDV-01 in NMIBC and FDA alignment on phase III program de-risk the pipeline. Financial position strengthened by a $100 million capital raise, supporting operations and clinical trials into 2028.
Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates
Positive 9-month follow-up data for NDV-01 showed a 92% overall response rate at any time in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety